Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Bristol-Myers Squibb Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (59)
Cancellation by sponsor (41)
Australian Public Assessment Report (AusPAR) (31)
Prescription medicine registration (26)
Prescription medicine evaluation (7)
Designation or determination (5)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (2)

Date

2024 (12)
2023 (6)
2022 (18)
2021 (9)
2020 (15)
2019 (4)
2018 (23)
2017 (18)
2016 (5)
2015 (14)
2014 (4)
2013 (7)
2012 (5)
2011 (10)
2010 (3)
2009 (3)
2007 (12)
2004 (1)
1993 (2)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

173 result(s) found, displaying 111 to 120

MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets blister pack Cancelled under s30(1)(c)

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets bottle Cancelled under s30(1)(c)

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 10/12.5 fosinopril 10mg and hydrochlorothiazide 12.5mg tablets blister pack Cancelled under s30(1)(c) of the Act

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 10/12.5 fosinopril 10mg and hydrochlorothiazide 12.5mg tablets bottle Cancelled under s30(1)(c) of the Act

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets blister pack Cancelled under s30(1)(c) of the Act

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets bottle Cancelled under s30(1)(c) of the Act

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
AusPAR: Ipilimumab (rch)

6 February 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ipilimumab (rch)
Bristol-Myers Squibb Australia Pty Ltd - Organ preservation solution Cancelled under s41GL(d) of the Act

20 February 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
Istodax (romidepsin) 10mg powder for injection vial, and solvent for reconstitution vial (198854)

7 August 2013

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Istodax (romidepsin) 10mg powder for injection vial, and solvent for reconstitution vial.
AusPAR: Nivolumab

23 August 2016

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Nivolumab

Pages

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.